Novo’s Stock Slide Cut Assets of Largest Shareholder by a Third

Novo Nordisk A/S’s slump last year slashed the asset value of the struggling drugmaker’s controlling shareholder by about a third, curtailing its ability to invest in up-and-coming biotechs.

By Ashleigh Furlong · Bloomberg

Novo Nordisk A/S’s slump last year slashed the asset value of the struggling drugmaker’s controlling shareholder by about a third, curtailing its ability to invest in up-and-coming biotechs.